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Editorial
The Enigma of Fatigue
Fatigue is an enigma: Everyone seems to know what it is,
but a detailed definition is hard to provide. Like water, it
slips away and cannot be grasped. There are no laboratory
tests, no magnetic resonance image can quantify it objec-
tively, and no specific treatment is available.
Fatigue is a common and often severe complaint. In the
adult US population, 9.4% have fatigue during at least one
month1, and as many as 22% of working adults were
fatigued in The Netherlands2, as summarized in the article
by Bergman, et al in this issue of The Journal3.
When a patient with rheumatoid arthritis (RA) starts talk-
ing about fatigue, the doctor will look for anemia, hypothy-
roidism, and other treatable explanations first. But when
fatigue persists, the doctor does not know what to say: as a
patient with RA recently told me, “Doctors do not seem able
to understand or to handle fatigue, so despite the fact it is
one of my main problems, I stopped talking about it in the
clinic.” This fits in with the findings of a postal question-
naire among Dutch rheumatologists4, and with in-depth
studies in UK patients, most of whom did not discuss fatigue
with their clinicians, but when they did they felt it was
dismissed5.
Fatigue is a significant problem for people with rheumat-
ic diseases as it contributes to many aspects of life. Studies
have found the prevalence of fatigue in RA patients to be
88%—98%6. Patients with osteoarthritis (OA) experience
notable amounts of fatigue and indicate it has substantial
impact on their lives7.
Fatigue can be both physical and cognitive, manifesting
as inability to think clearly, concentrate, or be motivated to
do anything5. Patients perceive their fatigue as unmanage-
able and unresolving, and professional support is rare8.
A distinction is drawn between fatigue and tiredness: a
person may be tired after exercise or straining work but
fatigue is more like exhaustion. Hewlett, et al use the
description by RA patients of overwhelming and uncontrol-
lable5, but a number of US dictionaries list fatigue and tired-
ness as synonyms. In the study from Bergman, et al3, the
measurement tool, a visual analog scale (VAS), includes
both words, which may cause some difficulties with
interpretation.
FATIGUE AS OUTCOME MEASURE?
Fatigue is recommended by OMERACT, by the European
League Against Rheumatism, and the American College of
Rheumatology as a patient centered outcome measure, and
it was proposed to add fatigue to the “core set” of outcome
measures of RA9,10. But can we really measure an enigma?
Large questionnaires have been developed to make sure
every aspect of the complaint is reflected, but a simple
fatigue VAS correlated with the Multidimensional
Assessment of Fatigue scale (alpha r = 0.80) and with the
FACIT (Functional Assessment of Chronic Illness Therapy)
fatigue scale (alpha r = 0.78)11,12.
The simple VAS appears to be a good method to meas-
ure fatigue, but what is one measuring? In the study from
Bergman and colleagues the question was arbitrarily chosen
as, “How much of a problem has fatigue or tiredness been
for you in the past week?”. Presumably the dual terminolo-
gy was chosen since in the USA the terms fatigue and tired-
ness are often seen as synonyms, and most patients do not
know the difference.
FATIGUE DOES NOT CORRELATE WITH
INFLAMMATION
Bergman, et al prove that levels of fatigue in the inflamma-
tory disorder RA are not significantly different from those
in the noninflammatory disorder OA, as measured with a
VAS. They do not differ in a clinical or in a research setting.
In fibromyalgia (FM) the values were substantially higher3.
Pain scores did not differ in RA versus OA but were higher
in FM. This very important finding adds to the enigma of
fatigue. The current study does not answer the question
whether fatigue in OAand RAcan be explained by the same
See Is fatigue an inflammatory variable in RA? page 2788
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factors and whether fatigue has the same meaning for both
groups.
It has been know for a long time that fatigue does not cor-
relate with erythrocyte sedimentation rate13, but Bergman
and colleagues show that fatigue is not an inflammatory
variable and has virtually no relationship with number of
swollen or tender joints. Regarding a moderate association
of fatigue with the Disease Activity Scale 28 (DAS28)
score, 79% could be explained by the patient global assess-
ment. Fatigue is not an inflammatory variable and has no
unique association with RA or RA therapy3.
PAIN AND FATIGUE
It has also been known for a long time that pain correlates
with fatigue, but it is interesting to learn that the patient
global, a question in the DAS28, correlates strongly with
fatigue and is probably to a large extent explained by pain3.
Fatigue correlates even more with pain than with patient
global3.
In recent clinical trials fatigue improved after treatment,
for example, in RA patients an improvement was seen after
24 weeks of 9.1 on a FACIT scale of 0—52, almost the same
as the 23.4 improvement in pain (VAS)14. Pollard, et al state
that fatigue in RA reflects pain and not disease activity15. In
a longitudinal study over a period of one year, fatigue was
associated with social stress in both patients and controls;
and in patients with RA fatigue was associated with anxiety,
less help at home, and more disability; in the multivariate
model, more bodily pain was no longer associated16. Some
patients stated during in-depth interviews that fatigue is
their worst RA symptom, whereas others experience pain as
the worst symptom5. These findings add to the enigma:
What is the relationship of pain and fatigue as perceived by
patients with RA?
WHAT EXPLAINS FATIGUE?
THE COMPOSITION OF FATIGUE
Bergman, et al3 showed that fatigue scores in OA and RA
are very similar; but the way they are composed might dif-
fer, and psychosocial factors may play a more important role
in RA than in OA. It is important to study the contribution
to fatigue of different factors in OA and RA and in other
rheumatic diseases, like Sjögren’s syndrome and systemic
lupus erythematosus, but it is likely that because of different
patient experiences and the use of language, different meas-
uring instruments may be needed for each disease.
Most studies find that fatigue in RA is explained to a
large extent by pain, but other factors play a role, including
learned helplessness, depression, and anxiety17,18. Wolfe, et
al showed that depression together with pain and sleep dis-
turbance are the strongest independent predictors of
fatigue6; Huyser, et al found that the best predictors of
increased fatigue were higher levels of pain, more depres-
sive symptoms, and female sex19. The level of fatigue is also
determined by self-efficacy towards coping with RA and
towards asking for help, and problematic social support,
which expresses itself in lack of sympathy or understanding
from the social network13. Sex, disease duration, functional
status, and affect appear not to be significant predictors13.
Fatigue is associated with illness severity and reduced qual-
ity of life, as found by Repping-Wuts, et al20.
WHAT DOES FATIGUE MEAN FOR THE
INDIVIDUAL PATIENT?
The perception of fatigue differs between men and women.
An in-depth interview study among 31 patients with RA
showed different patterns in emotions, consequences, and
management of fatigue between men and women. Mainly
women with multiple roles in daily life reported negative
consequences of fatigue, for example regarding mobility
and activity, social contacts, work, and stress. Men reported
fewer negative consequences than women, and none at all
for social contacts, work, or stress. These differences could
be related to the number of daily roles patients had to fulfil
(e.g., spouse, housekeeping, care for children, work). With
regard to coping with fatigue, a similar pattern was found:
women reported that they have to find a balance to be able
to cope with their fatigue while no men mentioned the need
for this strategy. Men reported no gender-specific coping
strategies21.
Some patients have no problem with fatigue. It is a chal-
lenge to look for the differences between these patients and
others who have difficulty in coping.
Patient perspective is very important regarding fatigue.
During the recent OMERACT meeting it was recommended
as a measure in all studies and work is under way, for exam-
ple, on the assessment of sleep22, but the study of Bergman
and colleagues again calls into question the usefulness of
fatigue as an outcome measure in clinical trials of medical
therapy.
There are many definitions of fatigue, but, as with pain,
the definition is not the most important issue in clinical
practice. Rather, the issue is the way fatigue can and should
be assessed, because quantifying fatigue enables us to study
fatigue20. It is important to develop a valid multidimension-
al fatigue questionnaire that is sensitive to change and dis-
criminates fatigue from pain and depression; such an instru-
ment would add to our insight into the causes and treatment
of fatigue.
THE ENIGMA UNVEILED?
Fatigue is an important problem for most patients with rheu-
matic conditions. Measuring fatigue adds to the clinician’s
understanding and to clinical care. It seems likely that
fatigue has a multicausal pathway, with various components
contributing different amounts in different patients at differ-
ent times22. Awareness of gender differences and patient’s
daily roles is also important in patient care and research21.
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Studies are needed to unveil the causes of this enigma and
to find solutions to help our patients.
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